Anika Therapeutics (ANIK) EBITDA (2010 - 2026)
Anika Therapeutics (ANIK) reported EBITDA of -$5.4 million for Q1 2026, down 28.95% year-over-year from -$7.6 million in Q1 2025, and down 2087.87% quarter-over-quarter from $272000.0 in Q4 2025.
Anika Therapeutics (ANIK) EBITDA (2010 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has 17 years of EBITDA data on file, last reported at -$5.4 million in Q1 2026.
- EBITDA for Q1 2026 came in at -$5.4 million, down 28.95% year-over-year; the trailing twelve-month figure through Mar 2026 was -$10.3 million (up 81.83% YoY), and the FY2025 annual result was -$9.1 million, up 84.17% from the prior year.
- EBITDA declined to -$5.4 million in Q1 2026 per ANIK's latest filing, from $272000.0 in the prior quarter.
- Over five years, EBITDA peaked at $272000.0 in Q4 2025 and troughed at -$62.4 million in Q4 2023.
- A 5-year average of -$10.0 million and a median of -$4.2 million in 2025 frame the typical range for EBITDA.
- The sharpest annual moves came in 2023 and 2025: EBITDA plunged 1518.55% in 2023, then surged 101.19% in 2025.
- A 5-year view of EBITDA shows it stood at -$3.9 million in 2022, then sank by 1518.55% to -$62.4 million in 2023, then jumped by 63.21% to -$22.9 million in 2024, then surged by 101.19% to $272000.0 in 2025, then sank by 2087.87% to -$5.4 million in 2026.
- Business Quant data shows ANIK's EBITDA at -$5.4 million in Q1 2026, $272000.0 in Q4 2025, and -$2.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 652.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 833.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 325.80 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | -681,231.97 |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 185.20 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 307.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -67.29 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -98.81 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 81.33 Mn |
| 10 | Anika Therapeutics | 197.89 Mn | 131.10 Mn | 19.00 Mn | -5.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.41 Mn |
| Dec 31, 2025 | 272,000.00 |
| Sep 30, 2025 | -2.51 Mn |
| Jun 30, 2025 | -2.62 Mn |
| Mar 31, 2025 | -4.19 Mn |
| Dec 31, 2024 | -22.95 Mn |
| Sep 30, 2024 | -29.20 Mn |
| Jun 30, 2024 | -189,000.00 |
| Mar 31, 2024 | -4.89 Mn |
| Dec 31, 2023 | -62.38 Mn |
| Sep 30, 2023 | -6.98 Mn |
| Jun 30, 2023 | -2.73 Mn |
| Mar 31, 2023 | -10.08 Mn |
| Dec 31, 2022 | -3.85 Mn |
| Sep 30, 2022 | -5.03 Mn |
| Jun 30, 2022 | -3.69 Mn |
| Mar 31, 2022 | -3.01 Mn |
| Dec 31, 2021 | -6.19 Mn |
| Sep 30, 2021 | 757,000.00 |
| Jun 30, 2021 | 6.73 Mn |